专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR100525759B1 바실러스 속 균주 유래의 폴리 감마 글루탐산합성유전자를 이용한 펩타이드 항생물질 Ｐ5와Ａｎａｌ3의 표면 발현 방법 및 그의 용도 失效
标题翻译：使用pgs A的肽P5和Anal3的表面 - 表达方法
公开(公告)号：KR100525759B1
公开(公告)日：2005-11-03
申请号：KR1020020063379
申请日：2002-10-17
申请人： 한국생명공학연구원 , 주식회사 바이오리더스 , 학교법인조선대학교
发明人： 성문희 , 홍승표 , 이종수 , 정창민 , 함경수 , 이동건 , 박윤경 , 김철중 , 부하령
IPC分类号： C12N15/63
摘要： 본 발명은 미생물 표면에 외래 단백질을 효율적으로 발현시킬 수 있는 표면 발현 모체로서 바실러스 속 균주에서 유래한 폴리 감마 글루탐산 합성에 관여하는 세포외막 단백질의 유전자(pgsBCA)를 이용하여 항균, 항진균, 항암활성을 나타내는 양친화성구조의 펩타이드 항생물질 P5와 Anal3를 세포표면에 발현시킨 미생물, 그들의 제조방법 및 그의 용도를 제공함에 관한 것이다.

2. 发明公开

KR1020040034780A 바실러스 속 균주 유래의 폴리 감마 글루탐산합성유전자를 이용한 펩타이드 항생물질 Ｐ5와Ａｎａｌ3의 표면 발현 방법 및 그의 용도 失效
标题翻译：使用PGS BCA基因的表达P5和ANAL3表达的方法
公开(公告)号：KR1020040034780A
公开(公告)日：2004-04-29
申请号：KR1020020063379
申请日：2002-10-17
申请人： 한국생명공학연구원 , 주식회사 바이오리더스 , 학교법인조선대학교
发明人： 성문희 , 홍승표 , 이종수 , 정창민 , 함경수 , 이동건 , 박윤경 , 김철중 , 부하령
IPC分类号： C12N15/63
CPC分类号： C12N15/70 , A61K35/747 , C12N15/746 , C12Y603/02
摘要： PURPOSE: A method for surface expression of peptides P5 and Anal3 using pgs BCA gene is provided, thereby removing a purification process of peptides P5 and Anal3, and using useful lactic acid bacteria for the surface expression, so that peptide antibiotics can be cheaply and stably mass-produced. CONSTITUTION: A surface expression vector of antibiotics pHCE1LB:pgsA-P5 comprises one or more genes encoding polygammaglutamic acid synthase complex selected from pgsB, pgsC and pgsA, and a gene dipolar peptide antibiotics having antimicrobial, antifungal and anticancer activities, wherein the dipolar peptide antibiotics has homology to the peptide P5 encoded by the nucleotide sequence set forth in SEQ ID NO: 4. Transformed microorganisms with the vector pHCE1LB:pgsA-P5, Escherichia coli(KCTC 10350BP) or Lactobacillus casei are provided. A pharmaceutical composition for antimicrobial, antifungal or anticancer comprises Lactobacillus casei on which the peptide P5 is surface expressed, or peptide P5 contained Lactobacillus floating matters as effective components. A surface expression vector of antibiotics pHCE1LB:pgsA-Anal3 comprises one or more genes encoding polygammaglutamic acid synthase complex selected from pgsB, pgsC and pgsA, and a gene dipolar peptide antibiotics having antimicrobial, antifungal and anticancer activities, wherein the dipolar peptide antibiotics has homology to the peptide Anal3 encoded by the nucleotide sequence set forth in SEQ ID NO: 6. Transformed microorganisms with the vector pHCE1LB:pgsA-Anal3, Escherichia coli(KCTC 10348BP) or Lactobacillus casei are provided. A pharmaceutical composition for antimicrobial, antifungal or anticancer comprises Lactobacillus casei on which the peptide Anal3 is surface expressed, or peptide Anal3 contained Lactobacillus floating matters as effective components.
摘要翻译：目的：提供使用pgs BCA基因表达肽P5和Anal3的方法，从而消除肽P5和Anal3的纯化过程，并使用有用的乳酸菌进行表面表达，使肽抗生素可以廉价稳定大规模生产的。构成：抗生素pHCE1LB：pgsA-P5的表面表达载体包含一种或多种编码选自pgsB，pgsC和pgsA的聚氨基丁酸合酶复合物的基因，以及具有抗微生物，抗真菌和抗癌活性的基因偶极肽抗生素，其中偶极肽抗生素与由SEQ ID NO：4所示的核苷酸序列编码的肽P5具有同源性。提供了具有载体pHCE1LB：pgsA-P5，大肠杆菌（KCTC 10350BP）或干酪乳杆菌的转化微生物。用于抗微生物，抗真菌或抗癌的药物组合物包括其上表达肽P5的干酪乳杆菌，或肽P5含有乳杆菌漂浮物作为有效成分。抗生素pHCE1LB：pgsA-Anal3的表面表达载体包含一个或多个编码选自pgsB，pgsC和pgsA的聚氨基丁酸合酶复合物的基因，以及具有抗微生物，抗真菌和抗癌活性的基因偶极肽抗生素，其中偶极肽抗生素具有同源性与由SEQ ID NO：6所示的核苷酸序列编码的肽Anal3进行比较。提供了具有载体pHCE1LB：pgsA-Anal3，大肠杆菌（KCTC 10348BP）或干酪乳杆菌的转化微生物。用于抗微生物，抗真菌或抗癌的药物组合物包括其上表达表达肽Anal3的干酪乳杆菌，或肽Anal3含有乳杆菌漂浮物作为有效成分。

3. 发明授权

KR100954882B1 조류 인플루엔자 바이러스 감염억제 효과를 가지는 신규 유산균 및 이를 포함하는 조성물 有权
标题翻译：新型乳酸菌预防禽流感感染及其组成
公开(公告)号：KR100954882B1
公开(公告)日：2010-04-28
申请号：KR1020090053845
申请日：2009-06-17
申请人： 주식회사 바이오리더스 , 한국생명공학연구원 , 충북대학교 산학협력단 , 충남대학교산학협력단 , 국민대학교산학협력단
发明人： 노종복 , 부하령 , 최영기 , 김철중 , 성문희
IPC分类号： C12N1/20 , A61K35/744 , A23C9/12 , A23K1/16 , A23L33/00
CPC分类号： C12R1/01 , A23K10/18 , A23K50/75 , A61K35/744 , C12N1/20 , A23C9/12 , A23L33/00
摘要： PURPOSE: A novel microorganism Weissella cibaria BLS13 is provided to ensure antiviral performance and use as a feed additive, a fermentation product, food, and a medicinal product. CONSTITUTION: A Weissella cibaria BLS13(KCTC11516BP) is isolated from Kimchi. An antiviral composition contains the Weissella cibaria BLS13(KCTC11516BP) or its culture liquid. A pharmaceutical composition for preventing an influenza infection contains KCTC11516BP or its culture liquid. The pharmaceutical composition is used in the form of a tablet, capsule, suppository, powder, gel, or liquid.
摘要翻译：目的：提供一种新型微生物Weissella cibaria BLS13，以确保抗病毒性能和用作饲料添加剂，发酵产品，食品和药用产品。构成：从泡菜泡菜中分离出一种贻贝BIS13（KCTC11516BP）。抗病毒组合物含有We aria aria aria BLS13（KCTC11516BP）或其培养液。用于预防流感感染的药物组合物含有KCTC11516BP或其培养液。药物组合物以片剂，胶囊，栓剂，粉剂，凝胶或液体的形式使用。

4. 发明公开

KR1020080086161A 신규 항시적 고발현 프로모터 및 그 용도 有权
标题翻译：新宪法强力促进者及其使用
公开(公告)号：KR1020080086161A
公开(公告)日：2008-09-25
申请号：KR1020070027947
申请日：2007-03-22
申请人： 주식회사 바이오리더스 , 한국생명공학연구원
发明人： 성문희 , 김철중 , 홍승표 , 부하령 , 이일한 , 김지연 , 김광
IPC分类号： C12N9/88 , C12N15/09 , C12N15/10
CPC分类号： C12N15/746 , C12N9/1276
摘要： A novel constitutive strong promoter is provided to express effectively a target protein on the surface of a microorganism transformed by an expression vector containing the promoter, so that the transformed microorganism is useful as a vaccine carrier. An aldolase promoter isolated from Lactobacillus casei has the nucleotide sequence of SEQ ID NO:1. A microorganism surface expression vector contains the aldolase promoter, polygammaglutamic acid synthetase complex gene selected from pgsA, pgsB and pgsC and a gene encoding a target protein. A method for producing a microorganism vaccine comprises the steps of: (a) transforming a microorganism with the microorganism surface expression vector and culturing the transformed microorganism to express an antigen on the surface of transformed microorganism; and (b) recovering the antigen surface-expressed microorganism, wherein the microorganism is a lactic acid bacterium.
摘要翻译：提供了一种新颖的组成型强启动子，以有效地表达由含有启动子的表达载体转化的微生物的表面上的靶蛋白，使得转化的微生物可用作疫苗载体。从干酪乳杆菌分离的醛缩酶启动子具有SEQ ID NO：1的核苷酸序列。微生物表面表达载体含有选自pgsA，pgsB和pgsC的醛缩酶启动子，聚氨基amic氨酸合成酶复合物基因和编码靶蛋白的基因。微生物疫苗的制造方法包括以下步骤：（a）用微生物表达载体转化微生物，培养转化的微生物以在转化的微生物的表面上表达抗原; 和（b）回收抗原表面表达微生物，其中微生物是乳酸菌。

5. 发明授权

KR100469800B1 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를이용한 표면 발현용 벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 有权
标题翻译：使用源自芽孢杆菌属的多聚谷氨酸合成酶基因的表面表达表达载体及使用其的表达蛋白质微生物表面的表达方法
公开(公告)号：KR100469800B1
公开(公告)日：2005-02-02
申请号：KR1020037016665
申请日：2002-08-09
申请人： 한국생명공학연구원 , 주식회사 바이오리더스 , (주)엠디랩
发明人： 성문희 , 홍승표 , 이종수 , 정창민 , 김철중 , 부하령 , 소다겐지 , 아시우치마코토
IPC分类号： C12N15/75
CPC分类号： C12N9/1051 , C07K2319/02 , C12N9/1288 , C12Y204/01133 , C12Y207/08005
摘要： The present invention relates to a surface expression vector having pgsBCA, a gene coding poly-gamma-glutamate synthetase and a method for expression of target protein at the surface of microorganism using the vector. The vector, in which foreign genes are inserted, transforms microorganisms and makes foreign proteins expressed stably on the surface of microorganisms.
摘要翻译：本发明涉及具有pgsBCA的载体表达载体，编码多聚-γ-谷氨酸合成酶的基因和使用该载体在微生物表面表达靶蛋白的方法。插入外源基因的载体转化微生物并使外源蛋白在微生物表面稳定表达。

6. 发明授权

KR100463350B1 신규 알카리성 리파제, 이를 생산하는 신규 바실러스 균주 및 리파제 대량생산 방법 失效
标题翻译： 신규알카리성리파제，이를생산하산신규바실러스균주및리파제대량생산방
公开(公告)号：KR100463350B1
公开(公告)日：2004-12-29
申请号：KR1020010061667
申请日：2001-10-06
申请人： 한국생명공학연구원 , 주식회사 바이오리더스
发明人： 성문희 , 오태광 , 김형권 , 최윤호 , 김광석 , 김영선 , 김철중 , 송재준 , 김광 , 배진우 , 신광순 , 부하령 , 이상철
IPC分类号： C12N9/14
摘要： PURPOSE: Provided are a novel alkaline lipase, a novel bacillus sp. strain producing the same, and a method of producing the lipase massively. The non-toxicity bacillus sp. strain is capable of being used in food industry, and the lipase is used for quantitative determination of lipid content. CONSTITUTION: The novel alkaline lipase shows thermostability at 40 deg.C and has an optimum temperature of activity at 35 deg.C. Further, it has no changes with calcium concentrations, and has an optimum activity at pH 8.5. Its amino acid sequence is represented by the SEQ ID NO:1. The novel bacillus sp. strain, bacillus pumilus B26 strain(KTCC 10081BP) produces the lipase. The lipase is mass-produced by transforming bacillus subtilis DB104 with a recombinant vector pMB26 then culturing the transformant. The transformant strain is bacillus subtilis DB104/pMB26(KCTC 10082BP).
摘要翻译：目的：提供了一种新型碱性脂肪酶，一种新型的芽孢杆菌。产生它的菌株，以及大量生产脂肪酶的方法。无毒芽孢杆菌菌株能够在食品工业中使用，并且脂肪酶用于定量测定脂质含量。构成：新型碱性脂肪酶在40摄氏度显示热稳定性，在35摄氏度时具有最佳活性温度。此外，钙浓度没有变化，并且在pH 8.5时具有最佳活性。其氨基酸序列由SEQ ID NO：1表示。新型芽孢杆菌菌株，短小芽孢杆菌B26菌株（KTCC10081BP）产生脂肪酶。通过用重组载体pMB26转化枯草芽孢杆菌DB104然后培养转化体来大量生产脂肪酶。转化株是枯草芽孢杆菌DB104 / pMB26（KCTC10082BP）。

7. 发明公开

KR1020120063025A Ｌ형 폴리감마글루탐산을 생산하는 신규 미생물 바실러스 메가테리움 토하 및 이로부터 생산된 Ｌ형 폴리감마글루탐산 有权
标题翻译：新型微生物生产L型聚氨基葡糖酸和L型聚氨基葡萄糖酸的新型微生物MOHATERIUM TOHA
公开(公告)号：KR1020120063025A
公开(公告)日：2012-06-15
申请号：KR1020100124020
申请日：2010-12-07
申请人： 주식회사 바이오리더스 , 국민대학교산학협력단 , 한국생명공학연구원 , 충남대학교산학협력단
发明人： 성문희 , 김철중 , 부하령 , 곽미선 , 박성빈 , 최동환 , 김지연
IPC分类号： C12N1/20 , C12P13/14 , A01N63/02 , C12R1/07
CPC分类号： C12R1/11 , A23L33/135 , A23L33/175 , A61K8/88 , A61K38/02 , A61K2800/10 , A61Q19/00 , C12N1/20 , C12P21/02
摘要： PURPOSE: A novel microorganism which produces L-type poly gamma glutamic acid is provided to obtain the poly gamma glutamic acid used as a thickening agent, and biodegradable plastic solvent. CONSTITUTION: A novel microorganism, Bacillus megaterium Toha(KCTC 11752BP), produces L-type poly gamma glutamic acid. The strain is derived from a fermented food. The strain has 16S rDNA sequence of sequence number 1 and produces the poly gamma glutamic acid at low salinity. A probiotic composition contains Bacillus megaterium Toha (KCTC 11752BP) and the poly gamma glutamic acid.
摘要翻译：目的：提供一种产生L-型polyγ谷氨酸的新型微生物，以获得用作增稠剂的聚γ谷氨酸和可生物降解的塑料溶剂。构成：一种新型微生物，巨大芽孢杆菌Toha（KCTC 11752BP）产生L-型polyγ谷氨酸。该菌株来自发酵食物。该菌株具有序列号1的16S rDNA序列，并产生低盐度的多聚谷氨酸。益生菌组合物含有巨大芽孢杆菌Toha（KCTC 11752BP）和聚γ谷氨酸。

8. 发明授权

KR100873179B1 폴리감마글루탐산을 함유하는 바이러스의 감염 억제용조성물 有权
标题翻译：用于预防包含多糖 - 谷氨酸的病毒感染的组合物
公开(公告)号：KR100873179B1
公开(公告)日：2008-12-10
申请号：KR1020070093093
申请日：2007-09-13
申请人： 주식회사 바이오리더스 , 한국생명공학연구원
发明人： 성문희 , 김철중 , 부하령 , 최영기 , 이일한 , 유대원
IPC分类号： A61K31/74 , A61K31/765 , A61P31/12
CPC分类号： A61K31/785 , A23K20/105 , A23L29/035 , A23L29/045 , A61K9/10 , Y10S514/888
摘要： A pharmaceutical composition for inhibiting or preventing the infection of virus, and a feed additive are provided to suppress the infection of virus inducing respiratory and systemic infection such as influenza virus. A pharmaceutical composition for inhibiting or preventing the infection of influenza virus comprises an effective amount of the poly-gamma-glutamic acid having a molecular weight of 3,000~15,000 kDa. Preferably the influenza is avian influenza. Preferably the poly-gamma-glutamic acid having a molecular weight of 3,000~15,000 kDa induces the secretion of IFN-beta.
摘要翻译：提供用于抑制或预防病毒感染的药物组合物和饲料添加剂，以抑制感染引起呼吸系统感染的病毒如流感病毒。用于抑制或预防流感病毒感染的药物组合物包含有效量的分子量为3,000〜15,000kDa的聚-γ-谷氨酸。优选地，流感是禽流感。优选分子量为3,000〜15,000kDa的聚-γ-谷氨酸诱导IFN-β的分泌。

9. 发明授权

KR100857861B1 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 有权
标题翻译： MYO-2肽多聚体和肌醇六磷酸融合蛋白的表面表达载体及其转化的微生物
公开(公告)号：KR100857861B1
公开(公告)日：2008-09-11
申请号：KR1020070103512
申请日：2007-10-15
申请人： 주식회사 바이오리더스 , 한국생명공학연구원 , 충남대학교산학협력단
发明人： 성문희 , 김철중 , 부하령 , 김지연 , 김영숙 , 허룡춘
IPC分类号： C07K16/00 , C07K19/00
CPC分类号： C07K14/475
摘要： A surface expression vector for fusion protein of Myo-2 peptide multimer and myostatin is provided to express the myostatin fusion protein on the surface of bacteria, and increase the blood antibody production, body weight and muscle amount of animals by orally administering the bacteria. A myostatin derived peptide Myo-2 has the amino acid sequence of SEQ ID NO:1. A Myo-2 peptide multimer is prepared by polymerizing 2-8 Myo-2 peptides. A fusion protein is prepared by fusing the Myo-2 peptide multimer with matured myostatin. A surface expression vector for fusion protein contains a gene encoding polygammaglutamic acid synthetase complex selected from pgsB(polygammaglutamic acid synthetase), pgsC and pgsA, the nucleotide sequence encoding the Myo-2 peptide multimer and a gene encoding the matured myostatin. A method for producing a fusion protein-surface expressed microorganism comprises the steps of: (a) expressing the fusion protein of myostatin derived peptide multimer and matured myostatin on the surface of microorganism by culturing a microorganism transformed with the surface expression vector; and (b) recovering the microorganism with surface expressed matured myostatin, wherein the microorganism is lactic acid bacterium. Further, the matured myostatin is be derived from mammal or birds.
摘要翻译：提供Myo-2肽多聚体和肌生成抑制素融合蛋白的表达表达载体，以表达细菌表面的肌生成抑制素融合蛋白，并通过口服施用细菌增加动物的血液抗体产生，体重和肌肉量。肌生长抑制素衍生肽Myo-2具有SEQ ID NO：1的氨基酸序列。通过聚合2-8个Myo-2肽制备Myo-2肽多聚体。通过将Myo-2肽多聚体与成熟的肌生成抑制素融合来制备融合蛋白。用于融合蛋白的表面表达载体包含编码聚腺苷酸合成酶复合物的基因，其选自pgsB（polygammaglutamic acid synthetase），pgsC和pgsA，编码Myo-2肽多聚体的核苷酸序列和编码成熟肌肉生长抑制素的基因。一种融合蛋白表面表达微生物的制备方法，包括以下步骤：（a）通过培养用表面表达载体转化的微生物，将肌生长抑制素衍生肽多聚体和成熟肌生成抑制素的融合蛋白表达在微生物表面上; 和（b）用表面表达成熟的肌生长抑制素回收微生物，其中微生物是乳酸菌。此外，成熟的肌生成抑制素来源于哺乳动物或鸟类。

10. 发明授权

KR100469936B1 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 失效
标题翻译： 사스바이러스항원의세포표면발현벡터및상기벡터에의해형질전환된미
公开(公告)号：KR100469936B1
公开(公告)日：2005-02-03
申请号：KR1020040040894
申请日：2004-06-04
申请人： 주식회사 바이오리더스 , (주)제노락 BL , 한국생명공학연구원 , (주)엠디랩
发明人： 성문희 , 김철중 , 정창민 , 홍승표 , 이종수 , 최재철 , 김광 , 주니치구로다 , 부하령
IPC分类号： C12N15/86
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/523 , C07K2319/00 , C12N9/93 , C12N15/74 , C12N2710/20022 , C12N2770/20022 , Y02A50/472 , Y02A50/476
摘要： The present invention relates to a surface expression vector of SARS coronavirus antigen containing a gene encoding an antigen of SARS inducing coronavirus and any one or two or more of genes pgsB, pgsC and pgsA encoding poly-gamma-glutamic acid synthase complex, a microorganism transformed by the surface expression vector, and a SARS vaccine comprising the microorganism. According to the present invention, it is possible to economically produce a vaccine for prevention and treatment of SARS using a recombinant strain expressing an SARS coronavirus antigen on their surface.
摘要翻译：本发明涉及含有编码SARS诱导冠状病毒抗原的基因的SARS冠状病毒抗原的表面表达载体和编码聚-γ-谷氨酸合成酶复合物的基因pgsB，pgsC和pgsA中的任意一种或两种或更多种，转化的微生物通过表面表达载体和包含该微生物的SARS疫苗。根据本发明，可以经济地生产使用在其表面上表达SARS冠状病毒抗原的重组菌株预防和治疗SARS的疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式